Dynamic Multi-Analyte Testing Technology for Accelerated Biomarker Measurement
Conference Recording May 06, 2013
About the Speaker
Patrick van den Bogaard followed his academic career in the molecular sciences with completing his PhD in molecular microbiology at the University of Wageningen. In 2008 Dr. van den Bogaard made the transfer to Philips Research he was responsible for the definition and design of the molecular assays for IVD. Patrick joined Biocartis SA on the first of January 2010 and holds the position of Director Life Sciences Research.
DMAT is a new and disruptive reaction platform, leveraging nanotechnologies, providing fast, high multiplexing, high quality protein and nucleic acid-based biomarker analysis. Digitally encoded microparticles are differentially coated with probes to capture the various analytes in an easy mix and match configuration. Uniting the reaction environment with the detection space into a single chamber greatly reduces assay hands-on time and time-to-result while it allows kinetic biomarker measurement. The proprietary micro-fluidic architecture improves mass-transfer to provide optimal reaction conditions and biomarkers are thereby detected truly as a function of their concentration. Allowing the multiplex measurement of proteins and nucleic acids, the microparticle platform is compatible with standard fluorescent immunoassay formats (including auto-antibody capture and epitope mapping) while amplified nucleic acid are detected on highly specific self-reporting particles. The resulting platform simplifies the detection of up to hundreds of different biomarkers in multiple samples in parallel producing more answers with less effort.